Amphastar Pharmaceuticals, which produces difficult-to-manufacture injectable and inhalable drugs, raised $56 million by offering 8.0 million shares at $7, below the range of $10 to $12. Amphastar Pharmaceuticals plans to list on the NASDAQ under the symbol AMPH. Amphastar Pharmaceuticals initially filed confidentially on 12/16/2013. Jefferies & Co., BMO Capital Markets and Piper Jaffray acted as lead managers on the deal.
